Related Experiment Video

Updated: May 17, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment

Patricia Mucci LoRusso1

  • 1Karmanos Cancer Institute/Wayne State University, Detroit, MI 48201, USA. lorussop@karmanos.org

Oncology
|November 7, 2012
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway can overcome drug resistance in breast cancer. Inhibitors like everolimus show promise in restoring sensitivity to endocrine therapy for advanced breast cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Endocrine receptor and HER2-targeted therapies are crucial for breast cancer treatment.
  • Drug resistance and disease progression remain significant challenges in advanced breast cancer.
  • The mammalian target of rapamycin (mTOR) pathway is implicated in cancer cell growth and drug resistance.

Purpose of the Study:

  • To review the role of the mTOR pathway in breast cancer development and therapeutic resistance.
  • To explore the translation of mTOR inhibitors from preclinical studies to clinical trials.
  • To discuss the potential of mTOR inhibitors in overcoming resistance to standard breast cancer therapies.

Main Methods:

  • Review of preclinical data on mTOR pathway inhibitors.
  • Analysis of clinical trial results for mTOR inhibitors in breast cancer.
  • Examination of the molecular mechanisms underlying mTOR pathway activation and resistance.

Main Results:

  • Overactivation of the mTOR pathway contributes to resistance against endocrine and HER2-targeted therapies.
  • mTOR inhibitors have demonstrated antitumorigenic effects in vitro and in vivo.
  • Everolimus, in combination with endocrine therapy, showed significant benefit in endocrine-resistant advanced breast cancer (e.g., BOLERO-2 study).

Conclusions:

  • Targeting the mTOR pathway is a rational strategy to overcome therapeutic resistance in breast cancer.
  • mTOR inhibitors represent a promising class of drugs for treating advanced and resistant breast cancer.
  • Further clinical development of mTOR inhibitors holds potential for improving patient outcomes in breast cancer.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...